The risk for seizures was nearly twice as high in patients with MS vs the general population and was potentially related to disease burden and S1PR modulators. Compared with the general population, ...
Electronic Science discusses high-intensity spatial-mode steerable frequency up-converter toward on-chip integration. ...
H3000 Factory Mk II and H3000 Band Delay Mk II plug-ins represent ‘the Holy Grail’ of DAW-based effects processing, ...
Title: Type 2 NKT Cells Directed Immune Regulatory Mechanism in Lupus Nephritis Presenter: Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio Session: 1180 – Parallel Session 24: ...
In parallel with the IND application, ENA has submitted ethics approval for a Phase 1b study in Australia. This study is expected to be initiated in mid-2024 with the aim to assess the safety, ...
Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...
Skyhawk Therapeutics Inc. signed on to work with Ipsen SA in a neurological disease-focused deal worth potentially $1.8 billion to discover and develop novel small molecules that modulate RNA. The ...
LA JOLLA, CA - GRI Bio, Inc. (NASDAQ: GRI), a biotechnology firm specializing in Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has been granted a patent ...
LA JOLLA, CA - GRI Bio, Inc. (NASDAQ: GRI), a biotechnology firm specializing in Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has been granted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback